caa a22 4500 47703781X CHVBK 20180405111309.0 cr unu---uuuuu 170330e19960901xx s 000 0 eng 10.1007/BF00046350 doi (NATIONALLICENCE)springer-10.1007/BF00046350 Vile Richard Imperial Cancer Research Fund Laboratory of Cancer Gene Therapy, St. Thomas' Hospital, London, UK aut Gene therapy for cancer, the course ahead [Elektronische Daten] [Richard Vile] Previous chapters have shown that there are a large number of therapeutic approaches under consideration for the gene therapy of cancer. Many of these have progressed into Phase I clinical trials. However, many of the early results are perceived to be disappointing in terms of low levels of gene transfer and systemic efficacy. In this concluding chapter, possible solutions to this state of unease are addressed, so that gene therapy of cancer can resume on its course to become a major contributor to clinical oncology in the years ahead. Kluwer Academic Publishers, 1996 gene therapy nationallicence cancer nationallicence Cancer and Metastasis Reviews Kluwer Academic Publishers 15/3(1996-09-01), 403-410 0167-7659 15:3<403 1996 15 10555 https://doi.org/10.1007/BF00046350 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00046350 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Vile Richard Imperial Cancer Research Fund Laboratory of Cancer Gene Therapy, St. Thomas' Hospital, London, UK aut NATIONALLICENCE 773 0- Cancer and Metastasis Reviews Kluwer Academic Publishers 15/3(1996-09-01), 403-410 0167-7659 15:3<403 1996 15 10555 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer